Find information on thousands of medical conditions and prescription drugs.

Invanz

Ertapenem is a carbapenem marketed by Merck as Invanz®. It is structurally very similar to meropenem in that it possess a 1-β-methyl group. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Indications

Ertapenem is designed to be effective against Gram negative bacteria. It is not active against MRSA, ampicillin-resistant enterococci, Pseudomonas aeruginosa or Acinetobacter species. Ertapenem also has clinically useful active against anaerobic bactera.

Ertapenem is marketed by Merck as first line treatment for community acquired infections. It should not be used as empirical treatment for hospital-acquired infections because of its lack of activity against Pseudomonas aeruginosa. In practice, it is reserved primarily for use against ESBL-producing and high level AmpC-producing Gram negative bacteria.

Dosing

Ertapenem is dosed as 1g given by intravenous injection over 30 minutes, or 1g diluted with 3.2ml of 1% lignocaine given intramuscularly. There is no oral preparation of ertapenem available. Ertapenem cannot be mixed with glucose.

The marketing slogan for ertapenem is "The Power of One", because the dose is one gram, once a day.

Pharmacokinetics

Unlike imipenem and meropenem, ertapenem is highly protein blound, which explains its long half life (4 hours).

Renal and hepatic dosing

Ertapenem is excreted primarily (80%) by the kidneys. Metabolism by the liver is not clinically important and does not affect dosing.

Patients on haemodialysis should be given ertapenem at least 6 hours before dialysis. If it is given less than six hours before dialysis, then the patient should be given an additional dose of 150mg IV after dialysis. Ideally, patients on haemodialysis should be given ertapenem immediately following dialysis.

Adverse effects

There are few adverse effects of ertapenem. The only absolute contra-indication is a previous anaphylactic reaction to ertapenem or other β-lactam antibiotic. There are no studies done in pregnant women, so the manufacturers cannot comment on its safety in pregnancy. There are no studies in children, and therefore there is no license for use in children aged under 18 years of age.

Use of all antibiotics is associated with increased rates of resistance (although carbapenem resistance is currently rare). There is particular worry that although ertapenem has no clinically useful activity against Pseudomonas aeruginosa, widespread use of ertapenem could still lead to increased carbapenem resistance in Pseudomonas (Livermore 2005).

Like all antibiotics, C. difficile colitis has been associated with its use.

Read more at Wikipedia.org


[List your site here Free!]


Once-daily ertapenem good for diabetic foot infections.(Clinical Rounds) : An article from: Skin & Allergy News $5.95

FDA Approves New Indication for INVANZ® for the Treatment of Moderate to Severe Complicated Foot Infection in Diabetic Patients without Osteomyelitis
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INVANZ(R) (ertapenem), ...
New drugs 2003
IN THIS ARTICLE, I'll acquaint you with seven new drugs marketed in the first half of 2002, including: * olmesartan medoxomil, a new angiotensin II receptor ...
FDA Grants Marketing Clearance for Invanz, a New Injectable Antibiotic Medicine from Merck
Business Editors/Health & Pharmaceutical Writers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Nov. 29, 2001 Merck & Co., Inc. announced today that ...
Significant FDA Approvals in 2001
The most urgent task faced by the U.S. Food and Drug Administration (FDA) in the wake of the terrorist attacks on September 11, 2001, was to assure the availability of medical products for the trea
Merck Anticipates Full-Year 2005 Earnings Per Share Range of $2.42 to $2.52; Reaffirms Fourth-Quarter and Full-Year 2004 EPS Guidance
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. --Merck expects continued growth in newer franchises, ZETIA and recently launched VYTORIN --Merck ...
[ BUSINESS BRIEFS ]
LTV agrees to keep making steel for now LTV Corp. agreed today to continue steel production until a bankruptcy court hearing next week on the long-term ...
Enanta Pharmaceuticals Appoints Yujiro Hata to Vice President of Business Development
Business Editors/Health/Medical Writers BIOWIRE2K WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 23, 2002 Enanta Pharmaceuticals Inc. (www.enanta.com), ...
Merck's Strong Performance in 2000 Driven by Five Key Medicines, Chairman Ray Gilmartin Tells Stockholders
Business Editors/Medical Writers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--April 24, 2001 Company's Pharmaceutical Sales Revenue Grew Fastest ...

Home Contact Resources Exchange Links ebay